First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US. The FDA’s Oncologic Drugs ...

AstraZeneca’s efforts to combine two of its top cancer drugs – Imfinzi and Lynparza – has been rewarded with positive results in an endometrial cancer study that could lead to regulatory ...

Neoplastic Agents Market Report 2025" has been added to ResearchAndMarkets.com's offering.This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, ...

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...

One woman's story of literal strength illustrates how ovarian cancer symptoms can be missed—and the lighthearted recovery ...

AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and ...

It does not impact other existing indications for Lynparza and the drug remains approved for the first-line maintenance treatment of BRCA-mutated advanced ovarian cancer and for HRD-positive advanced ...

(This August 31 story is refiled to add dropped word founding to Ertl's title in paragraph 13) By Allison Martell and Julie ...

The US Consumer Product Safety Commission (CPSC) just announced a recall of more than 2,300 bottles of a popular allergy medication due to a serious child poisoning risk. The problem isn’t with ...